We are live on ! Find out more
TSHA icon

Taysha Gene Therapies
TSHA

87 hedge funds and large institutions have $231M invested in Taysha Gene Therapies in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more call options, than puts

Call options by funds: $259K | Put options by funds: $61K

300% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 8

173% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 11

38% more funds holding

Funds holding: 63 → 87 (+24)

0.2% more ownership

Funds ownership: 69.52% → 69.72% (+0.2%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

44% less capital invested

Capital invested by funds: $411M → $231M (-$180M)

Holders
87
Holders Change
+24
Holders Change %
+38.1%
% of All Funds
1.27%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
32
Increased
30
Reduced
11
Closed
8
Calls
$259K
Puts
$61K
Net Calls
+$198K
Net Calls Change
+$76K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$6.74M
2
Citadel Advisors
Citadel Advisors
Florida
+$4.58M
3
TCM
Tybourne Capital Management
Hong Kong
+$4.39M
4
EP
Eversept Partners
New York
+$4.14M
5
BlackRock
BlackRock
New York
+$3.89M

Top Sellers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
-$16.3M
2
KCM
Kynam Capital Management
New Jersey
-$10.4M
3
OCA
Octagon Capital Advisors
New York
-$8.78M
4
VA
VR Adviser
New York
-$8.04M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
26
Alphabet Inc
California
$1.13M – – –
QPW
27
Quantum Private Wealth
Florida
$1.13M +$128K +64,140 +11%
PAI
28
Palo Alto Investors
California
$938K +$1.06M +529,861 New
Acadian Asset Management
29
Acadian Asset Management
Massachusetts
$813K +$917K +460,066 New
Morgan Stanley
30
Morgan Stanley
New York
$767K +$520K +261,007 +152%
Adage Capital Partners
31
Adage Capital Partners
Massachusetts
$743K -$2.15M -1,080,000 -72%
Citigroup
32
Citigroup
New York
$550K +$59.5K +29,844 +11%
MAM
33
Monaco Asset Management
Monaco
$522K +$588K +295,000 New
EC
34
EntryPoint Capital
New York
$516K +$581K +291,616 New
Kovitz Investment Group Partners
35
Kovitz Investment Group Partners
Illinois
$492K +$504K +252,778 +1,011%
Northern Trust
36
Northern Trust
Illinois
$378K +$294K +147,531 +223%
ACM
37
ADAR1 Capital Management
Texas
$370K +$417K +209,000 New
PCM
38
Prelude Capital Management
New York
$336K -$100K -50,375 -21%
PAMP
39
Polar Asset Management Partners
Ontario, Canada
$330K +$372K +186,700 New
TD Asset Management
40
TD Asset Management
Ontario, Canada
$311K – – –
State Street
41
State Street
Massachusetts
$253K +$6.38K +3,200 +2%
Two Sigma Investments
42
Two Sigma Investments
New York
$242K +$273K +136,973 New
Bank of America
43
Bank of America
North Carolina
$217K +$168K +84,148 +220%
Qube Research & Technologies (QRT)
44
Qube Research & Technologies (QRT)
United Kingdom
$210K +$236K +118,521 New
CPIG
45
Chicago Partners Investment Group
Illinois
$198K +$47.3K +23,740 +21%
Goldman Sachs
46
Goldman Sachs
New York
$148K +$166K +83,474 New
DC
47
Diametric Capital
Massachusetts
$122K -$1.38M -691,143 -91%
Squarepoint
48
Squarepoint
New York
$112K +$69.6K +34,909 +122%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$109K – – –
Bank of New York Mellon
50
Bank of New York Mellon
New York
$103K +$63.9K +32,066 +123%
1
2
3 4

TSHA Hedge Fund Activity: Q4 2023 in Review

87 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2023, worth a combined $231M — down 44% from $411M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new TSHA positions and 8 closed out — a net gain of 24 holders — while 30 added to existing stakes and 11 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $6.74M. The largest seller was TCG Crossover Management, cutting an estimated $16.3M.

  • 87 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2023, up from 63 in Q3 2023.
  • Funds reported $231M of Taysha Gene Therapies stock for Q4 2023, down 44% quarter-over-quarter.
  • 32 funds opened new Taysha Gene Therapies positions in Q4 2023 and 8 closed out, a net change of +24 holders.
  • The largest Taysha Gene Therapies buyer in Q4 2023 was Millennium Management, an estimated $6.74M added.
  • The largest Taysha Gene Therapies seller in Q4 2023 was TCG Crossover Management, an estimated $16.3M sold.

Based on aggregated 13F filings for Q4 2023.